GCP
MBX

GSA Capital Partners’s MBX Biosciences MBX Stock Holding History

GSA Capital Partners’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-19,295
Closed -$609K – 2239
2025
Q4 		$609K Buy
+19,295
New +$468K 0.05% 679
2025
Q2 		– Sell
-12,369
Closed -$91K – 2225
2025
Q1 		$91K Buy
+12,369
New +$131K 0.01% 1514

Other funds holding MBX

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

GSA Capital Partners's MBX Position: Q1 2026 in Review

GSA Capital Partners sold out of MBX Biosciences (MBX) in Q1 2026, closing a stake of 19,295 shares — an estimated $609K sold.

GSA Capital Partners first reported a position in MBX in Q1 2025 and held it in 2 quarters. The position peaked at $609K in Q4 2025. 157 funds tracked by Wall St. Rank hold MBX as of Q1 2026.

  • GSA Capital Partners reported no remaining MBX Biosciences position as of Q1 2026 after selling out during the quarter.
  • GSA Capital Partners sold 19,295 MBX Biosciences shares in Q1 2026, an estimated $609K.
  • GSA Capital Partners first reported a position in MBX Biosciences in Q1 2025 and held it in 2 quarters.
  • GSA Capital Partners's MBX Biosciences position peaked at $609K in Q4 2025.
  • 157 funds tracked by Wall St. Rank held MBX Biosciences as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.